Stockhead Investor Guide 2026
In this special investor guide, Tim Boreham showcases 25 pioneering Aussie health and biotech companies passing the clinical test, alongside insights from leading healthcare analysts from Morgans, Cannacord and Platinum Asset Management and Stockhead’s Nadine McGrath.
https://stockhead.com.au/investor-guides/investor-guide-health-biotech-2026-featuring-tim-boreham/
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Racura Oncology. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Racura Oncology a question about this update.